Skip to main content

Nasdaq IPOs

Solid tumor biotech Relay Therapeutics sets terms for $250 million IPO

6 years 2 months ago
Relay Therapeutics, a Phase 1 biotech developing small molecule therapies for solid tumors, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $250 million by offering 14.7 million shares at a price range of $16 to $18. At the midpoint of the
Renaissance Capital

The 2Q20 IPO Market's Law Firm Leaderboard

6 years 2 months ago
In the second quarter of 2020, 38 IPOs raised $15.1 billion, mostly in June as the market bounced back amid soaring IPO returns. The slow start to the quarter caused activity to decline from the 2Q19, when 62 IPOs raised $25.1 billion, boosted by Uber and other unicorns. Hea
Renaissance Capital

Health insurance marketplace GoHealth sets terms for $751 million IPO

6 years 2 months ago
GoHealth, a medicare-focused health insurance marketplace, announced terms for its IPO on Wednesday. The Chicago, IL-based company plans to raise $751 million by offering 39.5 million shares at a price range of $18 to $20. At the midpoint of the proposed range, GoHealth would com
Renaissance Capital

Tech SPAC ACE Convergence Acquisition files for a $200 million IPO

6 years 2 months ago
ACE Convergence Acquisition, a blank check company formed by ACE Equity Partners and industry veterans targeting a tech business, filed on Monday with the SEC to raise up to $200 million in an initial public offering. The Wilmington, DE-based company plans to raise $200 million b
Renaissance Capital

Cloud banking software provider nCino sets terms for $175 million IPO

6 years 2 months ago
nCino, which offers cloud-based software for financial institutions, announced terms for its IPO on Monday. The Wilmington, NC-based company plans to raise $175 million by offering 7.6 million shares at a price range of $22 to $24. At the midpoint of the proposed range, nCino wou
Renaissance Capital

Viral disease biotech AlloVir files for a $100 million IPO

6 years 2 months ago
AlloVir, a Phase 2 biotech developing allogeneic T cell therapies for viral diseases, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The company's pipeline contains lead candidate Viralym-M, a multi-virus-specific T cel
Renaissance Capital

French NASH biotech Inventiva sets terms for $102 million US IPO

6 years 2 months ago
Inventiva, a Phase 2 French biotech developing therapies for NASH and other diseases, announced terms for its IPO on Monday. The Daix, France-based company plans to raise $102 million by offering 7.5 million ADSs at $13.68, the as-converted last close of its shares on the Euronex
Renaissance Capital
Checked
19 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed